MBZUAI unveils the Institute of Digital Public Health, harnessing AI foundation models and a data-driven approach to drive innovation across computational biology, precision medicine, infectious disease monitoring, and the UAE Genome Atlas for transformative public health solutions.
OpenAI is in discussions with the FDA to explore leveraging AI, potentially through a project called cderGPT, to accelerate the drug approval process, with the FDA commissioner confirming the agency's first AI-assisted scientific review of a product.
Researchers have developed a groundbreaking method combining test-time augmentation and conformal prediction, enhancing AI model reliability by up to 30% for critical tasks like medical diagnosis, enabling more accurate and efficient decision-making in high-stakes scenarios.
Tempus AI unveils groundbreaking $200M deals with AstraZeneca and Pathos AI to build the largest AI model in oncology, harnessing multimodal data to drive biological insights, drug target discovery, and therapeutic development for cancer patients.
In a groundbreaking development, researchers have harnessed the power of AI and machine learning to analyze patient data, enabling the prediction of Alzheimer's disease up to 7 years before symptoms manifest, with high cholesterol and osteoporosis emerging as key predictors.
Breakthrough AI tools developed by Cambridge researchers can accurately predict cystic fibrosis progression, enabling personalized treatment plans tailored to individual patients' disease trajectories, competing health risks, and past cases, representing a major step towards precision healthcare.
In a groundbreaking development, the FDA has approved a key component of Precision Neuroscience's brain implant system, paving the way for paralyzed patients to potentially regain speech and movement through a cutting-edge brain-computer interface technology that rivals efforts by Neuralink, Synchron, and other prominent players.
Pioneering a privacy-first approach, researchers are developing secure AI agents that prioritize data minimization, encryption, and rigorous auditing to gain user trust, drive adoption in regulated sectors, and simplify compliance with privacy regulations like HIPAA, GDPR, and CCPA.
Researchers developed a multimodal AI tool that combines language models and graph-based models to efficiently design new molecules with desired properties from natural language queries, outperforming existing methods and potentially automating the entire molecule design and synthesis process.
In a groundbreaking collaboration, Ai2 and Google Cloud have jointly invested $20 million to establish the Cancer AI Alliance, leveraging AI's potential to accelerate cancer research through shared models and secure data analytics powered by Google's cloud infrastructure.